Credit Suisse’s TG Therapeutics TGTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $2.83M | Buy |
186,299
+758
| +0.4% | +$12.1K | ﹤0.01% | 1640 |
|
|
2023
Q4 | $3.17M | Sell |
185,541
-2,187
| -1% | -$25.4K | ﹤0.01% | 1612 |
|
|
2023
Q3 | $1.57M | Buy |
187,728
+5,709
| +3% | +$79.6K | ﹤0.01% | 1982 |
|
|
2023
Q2 | $4.52M | Buy |
182,019
+35,112
| +24% | +$907K | ﹤0.01% | 1404 |
|
|
2023
Q1 | $2.21M | Buy |
146,907
+9,212
| +7% | +$140K | ﹤0.01% | 1802 |
|
|
2022
Q4 | $1.63M | Buy |
137,695
+424
| +0.3% | +$3.08K | ﹤0.01% | 2002 |
|
|
2022
Q3 | $812K | Buy |
137,271
+14,851
| +12% | +$97.4K | ﹤0.01% | 2470 |
|
|
2022
Q2 | $520K | Sell |
122,420
-5,163
| -4% | -$32.2K | ﹤0.01% | 2814 |
|
|
2022
Q1 | $1.21M | Buy |
127,583
+6,439
| +5% | +$74.5K | ﹤0.01% | 2420 |
|
|
2021
Q4 | $2.3M | Buy |
121,144
+2,098
| +2% | +$54.5K | ﹤0.01% | 2685 |
|
|
2021
Q3 | $3.96M | Buy |
119,046
+1,288
| +1% | +$39.8K | ﹤0.01% | 2249 |
|
|
2021
Q2 | $4.57M | Sell |
117,758
-264,601
| -69% | -$10.4M | ﹤0.01% | 2163 |
|
|
2021
Q1 | $18.4M | Buy |
382,359
+189,490
| +98% | +$9.1M | 0.01% | 1206 |
|
|
2020
Q4 | $10M | Buy |
192,869
+29,727
| +18% | +$1M | ﹤0.01% | 1582 |
|
|
2020
Q3 | $4.37M | Sell |
163,142
-198,121
| -55% | -$4.56M | ﹤0.01% | 1881 |
|
|
2020
Q2 | $7.04M | Buy |
361,263
+233,273
| +182% | +$3.76M | 0.01% | 1491 |
|
|
2020
Q1 | $1.26M | Sell |
127,990
-32,527
| -20% | -$411K | ﹤0.01% | 2470 |
|
|
2019
Q4 | $1.78M | Buy |
160,517
+83,953
| +110% | +$638K | ﹤0.01% | 2696 |
|
|
2019
Q3 | $430K | Buy |
76,564
+27,059
| +55% | +$189K | ﹤0.01% | 3512 |
|
|
2019
Q2 | $428K | Sell |
49,505
-10,395
| -17% | -$78.6K | ﹤0.01% | 3492 |
|
|
2019
Q1 | $482K | Buy |
59,900
+10,721
| +22% | +$57.9K | ﹤0.01% | 3355 |
|
|
2018
Q4 | $202K | Buy |
49,179
+5,938
| +14% | +$29.5K | ﹤0.01% | 3667 |
|
|
2018
Q3 | $242K | Sell |
43,241
-13,133
| -23% | -$150K | ﹤0.01% | 3601 |
|
|
2018
Q2 | $741K | Sell |
56,374
-22,788
| -29% | -$313K | ﹤0.01% | 3220 |
|
|
2018
Q1 | $1.13M | Buy |
79,162
+12,269
| +18% | +$157K | ﹤0.01% | 2880 |
|
|
2017
Q4 | $548K | Sell |
66,893
-157,173
| -70% | -$1.37M | ﹤0.01% | 3383 |
|
|
2017
Q3 | $2.66M | Buy |
224,066
+23,514
| +12% | +$268K | ﹤0.01% | 2298 |
|
|
2017
Q2 | $2.02M | Buy |
200,552
+56,184
| +39% | +$629K | ﹤0.01% | 2225 |
|
|
2017
Q1 | $1.68M | Buy |
144,368
+90,748
| +169% | +$651K | ﹤0.01% | 2480 |
|
|
2016
Q4 | $250K | Sell |
53,620
-22,098
| -29% | -$130K | ﹤0.01% | 3732 |
|
|
2016
Q3 | $586K | Sell |
75,718
-116,618
| -61% | -$750K | ﹤0.01% | 3340 |
|
|
2016
Q2 | $1.17M | Buy |
192,336
+152,444
| +382% | +$1.24M | ﹤0.01% | 2792 |
|
|
2016
Q1 | $340K | Buy |
39,892
+4,704
| +13% | +$41.2K | ﹤0.01% | 3445 |
|
|
2015
Q4 | $420K | Buy |
35,188
+14,412
| +69% | +$182K | ﹤0.01% | 3510 |
|
|
2015
Q3 | $209K | Sell |
20,776
-60,382
| -74% | -$900K | ﹤0.01% | 3907 |
|
|
2015
Q2 | $1.35M | Buy |
81,158
+55,265
| +213% | +$875K | ﹤0.01% | 2900 |
|
|
2015
Q1 | $401K | Sell |
25,893
-19,126
| -42% | -$290K | ﹤0.01% | 3689 |
|
|
2014
Q4 | $713K | Buy |
45,019
+20,340
| +82% | +$265K | ﹤0.01% | 3433 |
|
|
2014
Q3 | $264K | Sell |
24,679
-13,887
| -36% | -$129K | ﹤0.01% | 3994 |
|
|
2014
Q2 | $362K | Buy |
+38,566
| New | +$247K | ﹤0.01% | 4001 |
|
|
2014
Q1 | – | Sell |
-11,014
| Closed | -$42K | – | 4839 |
|
|
2013
Q4 | $42K | Buy |
+11,014
| New | +$44.5K | ﹤0.01% | 4535 |
|
Other funds holding TGTX
SCM
OM
Credit Suisse's TGTX Position: Q1 2024 in Review
Credit Suisse increased its TG Therapeutics (TGTX) stake by 0.41% in Q1 2024, buying an estimated $12.1K and bringing the position to 186,299 shares worth $2.83M. The position accounts for ﹤0.01% of the portfolio, ranked #1640.
Credit Suisse first reported a position in TGTX in Q4 2013 and has held it in 41 quarters since. The position peaked at $18.4M in Q1 2021. 243 funds tracked by Wall St. Rank hold TGTX as of Q1 2024.
- Credit Suisse held 186,299 shares of TG Therapeutics worth $2.83M as of Q1 2024.
- Credit Suisse bought 758 TG Therapeutics shares in Q1 2024, an estimated $12.1K.
- TG Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1640 holding.
- Credit Suisse first reported a position in TG Therapeutics in Q4 2013 and has held it in 41 quarters since.
- Credit Suisse's TG Therapeutics position peaked at $18.4M in Q1 2021.
- 243 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.